MA31920B1 - 4- (4-CYANO-2-THIOARYL) -DIHYDROPYRIMIDINONE AND USE THEREOF - Google Patents
4- (4-CYANO-2-THIOARYL) -DIHYDROPYRIMIDINONE AND USE THEREOFInfo
- Publication number
- MA31920B1 MA31920B1 MA32921A MA32921A MA31920B1 MA 31920 B1 MA31920 B1 MA 31920B1 MA 32921 A MA32921 A MA 32921A MA 32921 A MA32921 A MA 32921A MA 31920 B1 MA31920 B1 MA 31920B1
- Authority
- MA
- Morocco
- Prior art keywords
- thioaryl
- cyano
- dihydropyrimidinone
- prevention
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/10—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
L'INVENTION CONCERNE : DE NOUVEAUX DÉRIVÉS DE 4-(4-CYANO-2-THIOARYLE)-DIHYDROPYRIMIDINE-2-ONE : DES PROCÉDÉS POUR LEUR FABRICATION ; LEUR UTILISATION SEULS OU EN COMBINAISONS POUR LE TRAITEMENT ET/OU LA PRÉVENTION DE MALADIES ET LEUR UTILISATION POUR LA FABRICATION DE MÉDICAMENTS POUR LE TRAITEMENT ET/OU LA PRÉVENTION DE MALADIES, EN PARTICULIER POUR LE TRAITEMENT ET/OU LA PRÉVENTION DE MALADIES DES POUMONS ET DU SYSTÈME CARDIOVASCULAIRE.THE INVENTION CONCERNED: NEW 4- (4-CYANO-2-THIOARYL) -DIHYDROPYRIMIDINE-2-ONE DERIVATIVES: PROCESSES FOR THEIR MANUFACTURE; THEIR USE ONLY OR IN COMBINATIONS FOR THE TREATMENT AND / OR PREVENTION OF DISEASES AND THEIR USE IN THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT AND / OR PREVENTION OF DISEASES, ESPECIALLY FOR THE TREATMENT AND / OR PREVENTION OF LUNG DISEASES AND OF THE CARDIOVASCULAR SYSTEM.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102007061766A DE102007061766A1 (en) | 2007-12-20 | 2007-12-20 | New 4-(4-cyano-2-thioaryl)-dihydro-pyrimidinone compounds are human neutrophil elastase inhibitor, useful for the treatment or prevention of e.g. pulmonary arterial hypertonia, acute lung injury and diseases of the cardiovascular system |
DE102008022521A DE102008022521A1 (en) | 2008-05-07 | 2008-05-07 | 1,4-Diaryl-pyrimidopyridazine-2,5-diones and their use |
DE102008052013A DE102008052013A1 (en) | 2008-10-17 | 2008-10-17 | New 4-(4-cyano-2-thioaryl)dihydropyrimidinone compounds are neutrophil elastase inhibitors useful to treat or prevent e.g. pulmonary arterial hypertension, chronic obstructive pulmonary disease, acute lung injury, or cystic fibrosis |
PCT/EP2008/010411 WO2009080199A1 (en) | 2007-12-20 | 2008-12-09 | 4-(4-cyano-2-thioaryl)dihydropyrimidinones and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MA31920B1 true MA31920B1 (en) | 2010-12-01 |
Family
ID=40394273
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA32921A MA31920B1 (en) | 2007-12-20 | 2010-06-16 | 4- (4-CYANO-2-THIOARYL) -DIHYDROPYRIMIDINONE AND USE THEREOF |
Country Status (39)
Country | Link |
---|---|
US (3) | US8288402B2 (en) |
EP (1) | EP2234985B1 (en) |
JP (1) | JP5519526B2 (en) |
KR (2) | KR101712786B1 (en) |
CN (2) | CN103204815B (en) |
AR (1) | AR069765A1 (en) |
AT (1) | ATE548355T1 (en) |
AU (1) | AU2008340733B9 (en) |
BR (1) | BRPI0821027B8 (en) |
CA (1) | CA2709786C (en) |
CL (1) | CL2008003691A1 (en) |
CO (1) | CO6280490A2 (en) |
CR (1) | CR11472A (en) |
CY (1) | CY1112813T1 (en) |
DK (1) | DK2234985T3 (en) |
DO (1) | DOP2010000165A (en) |
EC (1) | ECSP10010216A (en) |
ES (1) | ES2382143T3 (en) |
HK (2) | HK1146485A1 (en) |
HR (1) | HRP20120457T1 (en) |
IL (2) | IL205742A (en) |
JO (1) | JO2756B1 (en) |
MA (1) | MA31920B1 (en) |
MX (1) | MX2010006033A (en) |
MY (1) | MY150285A (en) |
NZ (1) | NZ586263A (en) |
PE (1) | PE20091429A1 (en) |
PL (1) | PL2234985T3 (en) |
PT (1) | PT2234985E (en) |
RS (1) | RS52270B (en) |
RU (1) | RU2497813C2 (en) |
SG (2) | SG186679A1 (en) |
SI (1) | SI2234985T1 (en) |
SV (1) | SV2010003581A (en) |
TN (1) | TN2010000288A1 (en) |
TW (1) | TWI455715B (en) |
UY (1) | UY31526A1 (en) |
WO (1) | WO2009080199A1 (en) |
ZA (1) | ZA201004239B (en) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008126920A1 (en) * | 2007-04-11 | 2008-10-23 | Ajinomoto Co., Inc. | Remedy for diabetes |
MX2010006033A (en) * | 2007-12-20 | 2010-07-16 | Bayer Schering Pharma Ag | 4-(4-cyano-2-thioaryl)dihydropyrimidinones and use thereof. |
DE102009016553A1 (en) * | 2009-04-06 | 2010-10-07 | Bayer Schering Pharma Aktiengesellschaft | Sulfonamide- and sulfoximine-substituted diaryldihydropyrimidinones and their use |
GB201004178D0 (en) * | 2010-03-12 | 2010-04-28 | Pulmagen Therapeutics Inflamma | Enzyme inhibitors |
GB201004179D0 (en) * | 2010-03-12 | 2010-04-28 | Pulmagen Therapeutics Inflamma | Enzyme inhibitors |
DE102010030187A1 (en) | 2010-06-16 | 2011-12-22 | Bayer Schering Pharma Aktiengesellschaft | New 4-cyano-2-sulfonylphenyl-pyrazolyl-substituted pyridinones and pyrazinones compounds are human neutrophil elastase inhibitors, useful to treat and prevent e.g. pulmonary arterial hypertension and chronic obstructive pulmonary disease |
MX2014002285A (en) | 2011-08-26 | 2017-01-06 | Southern Res Inst | Hiv replication inhibitors. |
CN103373951B (en) * | 2012-04-28 | 2016-03-09 | 上海医药工业研究院 | A kind of preparation method of lapatinib intermediate |
US9815815B2 (en) | 2013-01-10 | 2017-11-14 | Pulmokine, Inc. | Non-selective kinase inhibitors |
US20140221335A1 (en) * | 2013-02-06 | 2014-08-07 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
US9115093B2 (en) | 2013-03-04 | 2015-08-25 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
EP3054937B1 (en) | 2013-10-11 | 2023-07-26 | Pulmokine, Inc. | Spray dry formulations |
USRE47493E1 (en) | 2014-02-20 | 2019-07-09 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
EP3126339A1 (en) | 2014-04-03 | 2017-02-08 | Bayer Pharma Aktiengesellschaft | 2,5-disubstituted cyclopentane carboxylic acids and use thereof |
JP2017509665A (en) | 2014-04-03 | 2017-04-06 | バイエル ファーマ アクチエンゲゼルシャフト | 2,5-Disubstituted cyclopentanecarboxylic acids for the treatment of airway diseases |
EP3126340A2 (en) | 2014-04-03 | 2017-02-08 | Bayer Pharma Aktiengesellschaft | Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and use thereof |
US9657015B2 (en) | 2014-07-31 | 2017-05-23 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
US9290457B2 (en) * | 2014-07-31 | 2016-03-22 | Boehringer Ingelheim International Gmbh | Substituted dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
US9458113B2 (en) * | 2014-07-31 | 2016-10-04 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
US9440930B2 (en) * | 2014-07-31 | 2016-09-13 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
US9475779B2 (en) * | 2014-07-31 | 2016-10-25 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
WO2016050835A2 (en) * | 2014-10-02 | 2016-04-07 | Ruprecht-Karls-Universität Heidelberg | Selective inhibitors of neutrophil elastase for treating neuropathic pain and chronic pain states harbouring a neuropathic component |
AU2016232270B2 (en) | 2015-03-18 | 2020-09-03 | Ph Pharma Co., Ltd. | Method for producing (4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro pyrimidine-5-carbonitrile |
WO2016176399A1 (en) * | 2015-04-28 | 2016-11-03 | Stc.Unm | Compositions and methods for treatment of pulmonary hypertension |
US20190008867A1 (en) * | 2015-11-13 | 2019-01-10 | Ph Pharma Co., Ltd. | 4-(4-cyano-2-thioaryl)dihydropyrimidinones for treating chronic wounds |
JP2020500183A (en) | 2016-10-27 | 2020-01-09 | プルモキネ、インコーポレイテッド | Combination therapy for the treatment of pulmonary hypertension |
US9856232B1 (en) | 2017-06-20 | 2018-01-02 | King Saud University | Dihydropyrimidinone derivatives |
CA3101274A1 (en) * | 2018-04-24 | 2019-10-31 | Ph Pharma Co., Ltd. | Use of neutrophil elastase inhibitors in liver disease |
GB201820450D0 (en) | 2018-12-14 | 2019-01-30 | Z Factor Ltd | Compound and its use for the treatment of alpha1-antitryspin deficiency |
MX2022002054A (en) * | 2019-08-23 | 2022-08-08 | Ph Pharma Co Ltd | Use of a neutrophil elastase inhibitor in lung disease. |
CN111978179A (en) * | 2020-08-27 | 2020-11-24 | 青岛科技大学 | Synthetic method of 6-hydroxyhexanoate |
WO2022076881A1 (en) * | 2020-10-09 | 2022-04-14 | The Regents Of The University Of California | Methods of treating alzheimer's disease using slow tight binding soluble epoxide hydrolase inhibitors |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUT42077A (en) * | 1985-06-03 | 1987-06-29 | Squibb & Sons Inc | Process for producing diesters of 2-tioxo- or 2-oxo-pyrimidine-1,5-dicarboxylic acid and 1-acyl-pyrimidine-5-carboxylic acids and esters |
US4738965A (en) * | 1987-02-03 | 1988-04-19 | Institut Organischskogo Sinteza Akademii Nauk Ssr | 2-oxo-4-(2'-difluoromethylthiophenyl)-5-methoxycarbonyl-6-methyl-1,2,3,4-tetrahydropyrimidine |
GB9214053D0 (en) | 1992-07-02 | 1992-08-12 | Ici Plc | Heterocyclic amides |
JP2000507545A (en) * | 1996-03-25 | 2000-06-20 | スミスクライン・ビーチャム・コーポレイション | Novel treatment for CNS injury |
BR0013427A (en) * | 1999-08-19 | 2002-07-30 | Nps Pharma Inc | Heteropolyclic Compounds and Their Uses as Metabotropic Glutamate Receptor Antagonists |
MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
GB0219896D0 (en) | 2002-08-27 | 2002-10-02 | Bayer Ag | Dihydropyridine derivatives |
GB2392910A (en) * | 2002-09-10 | 2004-03-17 | Bayer Ag | 2-Oxopyrimidine derivatives and their use as human leukocyte elastase inhibitors |
US7566723B2 (en) | 2002-09-10 | 2009-07-28 | Bayer Healthcare Ag | 1-phenyl1-3,4-dihydropyrimidin-2(1H)-one derivatives and their use |
PL375647A1 (en) * | 2002-09-10 | 2005-12-12 | Bayer Healthcare Ag | Pyrimidinone derivatives as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes |
US7166603B2 (en) | 2003-07-23 | 2007-01-23 | Bristol-Myers Squibb Co. | Dihydropyrimidone inhibitors of calcium channel function |
JP4825194B2 (en) * | 2004-02-26 | 2011-11-30 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | 1,4-Diaryl-dihydropyrimidin-2-one compounds and their use as human neutrophil elastase inhibitors |
WO2005082863A2 (en) * | 2004-02-26 | 2005-09-09 | Bayer Healthcare Ag | 1,4 diaryl-dihydropyrimidin-2 ones and their use as a human neutrophil elastase inhibitors |
JP2007530690A (en) * | 2004-03-29 | 2007-11-01 | メルク エンド カムパニー インコーポレーテッド | Diaryltriazoles as inhibitors of 11-β-hydroxysteroid dehydrogenase-1 |
GB0502258D0 (en) | 2005-02-03 | 2005-03-09 | Argenta Discovery Ltd | Compounds and their use |
GB0512940D0 (en) | 2005-06-24 | 2005-08-03 | Argenta Discovery Ltd | Compounds and their use |
GB0520743D0 (en) | 2005-10-12 | 2005-11-23 | Argenta Discovery Ltd | Compounds and their use |
WO2007129060A1 (en) | 2006-05-04 | 2007-11-15 | Argenta Discovery Limited | Tetrahydropyrrolopyrimidinediones and their use as human neutrophil elastase inhibitors |
US20100010024A1 (en) | 2006-07-01 | 2010-01-14 | Bayer Healthcare Ag | Use of1,4-diaryl-dihydropyrimidine-2-on derivatives for treating pulmonary arterial hypertension |
EP2064184A1 (en) | 2006-09-04 | 2009-06-03 | AstraZeneca AB | Multimeric heterocyclic compounds useful as neutrophil elastase inhibitors |
DE102008022521A1 (en) * | 2008-05-07 | 2009-11-12 | Bayer Schering Pharma Aktiengesellschaft | 1,4-Diaryl-pyrimidopyridazine-2,5-diones and their use |
MX2010006033A (en) * | 2007-12-20 | 2010-07-16 | Bayer Schering Pharma Ag | 4-(4-cyano-2-thioaryl)dihydropyrimidinones and use thereof. |
DE102009016553A1 (en) * | 2009-04-06 | 2010-10-07 | Bayer Schering Pharma Aktiengesellschaft | Sulfonamide- and sulfoximine-substituted diaryldihydropyrimidinones and their use |
-
2008
- 2008-12-09 MX MX2010006033A patent/MX2010006033A/en active IP Right Grant
- 2008-12-09 EP EP08864824A patent/EP2234985B1/en active Active
- 2008-12-09 US US12/809,781 patent/US8288402B2/en active Active
- 2008-12-09 CA CA2709786A patent/CA2709786C/en active Active
- 2008-12-09 MY MYPI2010002687A patent/MY150285A/en unknown
- 2008-12-09 DK DK08864824.1T patent/DK2234985T3/en active
- 2008-12-09 KR KR1020167021839A patent/KR101712786B1/en active IP Right Grant
- 2008-12-09 JP JP2010538407A patent/JP5519526B2/en active Active
- 2008-12-09 KR KR1020107016069A patent/KR101649381B1/en active Application Filing
- 2008-12-09 PL PL08864824T patent/PL2234985T3/en unknown
- 2008-12-09 BR BRPI0821027A patent/BRPI0821027B8/en active IP Right Grant
- 2008-12-09 RS RS20120213A patent/RS52270B/en unknown
- 2008-12-09 RU RU2010129724/04A patent/RU2497813C2/en active
- 2008-12-09 AU AU2008340733A patent/AU2008340733B9/en active Active
- 2008-12-09 SG SG2012094132A patent/SG186679A1/en unknown
- 2008-12-09 PT PT08864824T patent/PT2234985E/en unknown
- 2008-12-09 WO PCT/EP2008/010411 patent/WO2009080199A1/en active Application Filing
- 2008-12-09 SI SI200830619T patent/SI2234985T1/en unknown
- 2008-12-09 CN CN201310122598.7A patent/CN103204815B/en active Active
- 2008-12-09 ES ES08864824T patent/ES2382143T3/en active Active
- 2008-12-09 CN CN2008801216561A patent/CN101903356B/en active Active
- 2008-12-09 AT AT08864824T patent/ATE548355T1/en active
- 2008-12-09 NZ NZ586263A patent/NZ586263A/en unknown
- 2008-12-09 SG SG10201604819TA patent/SG10201604819TA/en unknown
- 2008-12-11 CL CL2008003691A patent/CL2008003691A1/en unknown
- 2008-12-11 PE PE2008002054A patent/PE20091429A1/en active IP Right Grant
- 2008-12-11 UY UY31526A patent/UY31526A1/en active IP Right Grant
- 2008-12-15 AR ARP080105447A patent/AR069765A1/en active IP Right Grant
- 2008-12-18 JO JO2008569A patent/JO2756B1/en active
- 2008-12-19 TW TW097149556A patent/TWI455715B/en not_active IP Right Cessation
-
2010
- 2010-05-13 IL IL205742A patent/IL205742A/en active IP Right Grant
- 2010-05-28 EC EC2010010216A patent/ECSP10010216A/en unknown
- 2010-06-02 CR CR11472A patent/CR11472A/en unknown
- 2010-06-02 SV SV2010003581A patent/SV2010003581A/en unknown
- 2010-06-02 DO DO2010000165A patent/DOP2010000165A/en unknown
- 2010-06-02 CO CO10066579A patent/CO6280490A2/en not_active Application Discontinuation
- 2010-06-15 ZA ZA2010/04239A patent/ZA201004239B/en unknown
- 2010-06-16 MA MA32921A patent/MA31920B1/en unknown
- 2010-06-18 TN TN2010000288A patent/TN2010000288A1/en unknown
-
2011
- 2011-01-21 HK HK11100646.5A patent/HK1146485A1/xx unknown
-
2012
- 2012-05-29 HR HRP20120457AT patent/HRP20120457T1/en unknown
- 2012-05-31 CY CY20121100495T patent/CY1112813T1/en unknown
- 2012-09-12 US US13/612,435 patent/US8889700B2/en active Active
-
2013
- 2013-09-02 HK HK13110227.9A patent/HK1183018A1/en unknown
-
2014
- 2014-10-23 US US14/522,510 patent/US9174997B2/en active Active
- 2014-11-18 IL IL235754A patent/IL235754A/en active IP Right Grant
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA31920B1 (en) | 4- (4-CYANO-2-THIOARYL) -DIHYDROPYRIMIDINONE AND USE THEREOF | |
MA31570B1 (en) | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | |
MA33123B1 (en) | 2-Astmedo-5-aryl-1,2,4-triazolone substitute and its use | |
MA32226B1 (en) | Compositions and their methods of preparation and use | |
MA30914B1 (en) | SUBSTITUTED DIHYDROPYRAZOLONES FOR THE TREATMENT OF CARDIOVASCULAR AND HEMATOLOGICAL DISEASES. | |
MA34721B1 (en) | SUBSTITUTED 1-BENZYLCYCLOALKYL CARBOXYLIC ACIDS AND USE THEREOF | |
TNSN07063A1 (en) | THERAPEUTIC USES OF RTP801 INHIBITORS | |
MA31231B1 (en) | Antibodies and anti-robo4 antibodies and their uses. | |
IN2005DE03350A (en) | ||
MA31535B1 (en) | SUBSTITUTED (OXAZOLIDINON-5-YL-METHYL) -2-THIOPHENER CARBOXAMIDES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | |
MA30868B1 (en) | 2-AMINOCARBONYL-PYRIDINE DERIVATIVES | |
WO2006105516A3 (en) | Compositions and methods for diagnosing and treating neuropsychiatric disorders | |
WO2007109236A3 (en) | Microrna fingerprints during human megakaryocytopoiesis | |
CY1111437T1 (en) | Tetrahydropyrrolopyrimidinodionides and their use as inhibitors of human hydrophilic elastase | |
MA27794A1 (en) | SUBSTITUTED DIHYDROQUINAZOLINES WITH ANTIVIRAL PROPERTIES | |
JO2828B1 (en) | Anti-Hepcidin Antibodies and Uses Thereof | |
FR2886851B1 (en) | COMPOSITION BASED ON AVERMECTIN AND METRONIDAZOLE, IN PARTICULAR FOR THE TREATMENT OF ROSACEA | |
MA38349A1 (en) | Estra-1,3,5 (10), 16-tetraeno-3-carboxamide to inhibit 17-beta-hydroxysteroid dehydrogenase (akr1c3) | |
MA37742A1 (en) | Derivatives of 3-substituted oestra-1,3,5 (10), 16-tetraene, processes for their preparation, pharmaceutical preparations containing them, and their use in the manufacture of medicaments | |
MA33290B1 (en) | SUBSTITUTED PIPERIDINES | |
MA30039B1 (en) | NOVEL ACYCLIC SUBSTITUTED FUROPYRIMIDINE DERIVATIVES AND THEIR USE FOR TREATING CARDIOVASCULAR DISEASES | |
WO2006060542A3 (en) | Formulations of substituted benzoxazoles | |
DE502007004579D1 (en) | ARYL-SUBSTITUTED HETEROCYCLES AND THEIR USE | |
ATE511512T1 (en) | OLANZAPIN PAMOATE DIHYDRATE | |
MA33291B1 (en) | SUBSTITUTED PIPERIDINES |